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Abstract 
Acute heart failure and in particular, cardiogenic shock are associated with high morbidity and 
mortality. A therapeutic dilemma is that the use of positive inotropic agents, such as 
catecholamines or phosphodiesterase-inhibitors, is associated with increased mortality. Newer 
drugs, such as levosimendan or omecamtiv mecarbil, target sarcomeres to improve systolic 
function putatively without elevating intracellular Ca2+. Although meta-analyses of smaller trials 
suggested that levosimendan is associated with a better outcome than dobutamine, larger 
comparative trials failed to confirm this observation. For omecamtiv mecarbil, phase II clinical 
trials suggest a favorable hemodynamic profile in patients with acute and chronic heart failure, 
and a phase III morbidity/mortality trial in patients with chronic heart failure has recently begun. 
Here, we review the pathophysiological basis of systolic dysfunction in patients with heart 
failure and the mechanisms through which different inotropic agents improve cardiac function. 
Since adenosine triphosphate and reactive oxygen species production in mitochondria are 
intimately linked to the processes of excitation-contraction coupling, we also discuss the impact 
of inotropic agents on mitochondrial bioenergetics and redox regulation. Therefore, this 
position paper should help identify novel targets for treatments that could not only safely 
improve systolic and diastolic function acutely, but potentially also myocardial structure and 
function over a longer term.   
 
Key words 
Heart failure, acute decompensated heart failure, inotropes, cardiogenic shock, excitation-
contraction coupling, calcium, sarcomeres, mitochondria, energetics, adrenergic receptors, 
contractility, levosimendan, omecamtiv mecarbil, nitroxyl.  
 
 
 
 
 
 
  
3 
 
Introduction 
Heart failure (HF) is a leading cause for hospital admissions in developed countries 
worldwide,1 and its incidence is further increasing as average life expectancy rises. While the 
prognosis of patients with chronic HF has improved over the last decades, the prognosis of 
acute HF is still poor. Although only a small percentage of patients with acute HF present 
with cardiogenic shock (~3%) and/or signs of hypoperfusion (~15%), their in-hospital 
mortality is much higher than of patients with acute HF without these severe conditions.2 An 
important treatment option in these patients are inotropic agents to acutely increase cardiac 
output.3 However, since the use of most inotropic agents (in particular, catecholamines and 
PDE-inhibitors) is complicated by adverse short- and long-term effects, their use is not 
recommended in the absence of hypotension or hypoperfusion.3 On the other hand, the 
oldest inotropic agent (digitalis) can be safely applied to patients with chronic HF and 
improves morbidity.4 […] Here, we discuss the detailed mechanisms of inotropic agents to 
estimate which mechanisms of action may provide benefit in either acute or chronic HF.  
 
In patients with HF with reduced ejection fraction (HFrEF), the inability of the heart to eject 
sufficient blood for the needs of peripheral tissues is caused by defects of excitation-
contraction (EC) coupling in cardiac myocytes (Figure 1).5 Traditionally, an acute increase in 
cardiac output is achieved with drugs that increase intracellular cyclic adenosine 
monophosphate (cAMP), such as catecholamines or phosphodiesterase (PDE) inhibitors 
(Figure 2). However, these agents increase myocardial oxygen (O2) consumption, 
predispose to life-threatening arrhythmias6 and activate signaling pathways of hypertrophy 
and cell death,7,8 which may explain why they are associated with adverse outcome.9 
Consequently, recent developments aimed at increasing contractility without increasing 
cAMP or Ca2+ through Ca2+-sensitizing of myofilaments or myosin activation. Although meta-
analyses with the Ca2+ sensitizer levosimendan suggest an overall benefit,10,11 larger 
comparative trials failed to show a survival benefit despite hemodynamic improvements.12-15 
The myosin activator omecamtiv mecarbil has passed phase II trials,16-20 and a phase III trial 
was recently launched in patients with chronic HF (GALACTIC-HF; NCT0292932).   
 
Considering the poor outcome of patients in cardiogenic shock and/or signs of hypoperfusion2 
and the mostly disappointing results of inotropic agents in patients with acute HF, novel 
strategies are urgently needed. To this end, the Committees on Translational Research and 
on Acute Heart Failure of the Heart Failure Association (HFA) of the European Society of 
Cardiology (ESC) developed this position paper that addresses the following three key 
issues:  
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1) Why have classical inotropic agents failed?  
2) Is direct targeting of sarcomere function therapeutically advantageous? 
3) Which novel concepts are promising? 
 
To understand the mechanisms of traditional, current and future medicines, it is essential to 
understand the physiology of EC coupling and its pathological alterations in HF. We will also 
discuss the bioenergetic consequences of inotropic interventions, since these may impact 
the long-term prognosis of HF patients. Finally, we will give recommendations for basic and 
clinical research directed at developing novel strategies for inotropic interventions in acute 
HF.   
 
 
Physiology of excitation-contraction coupling 
During each action potential, Ca2+ enters cardiac myocytes via L-type Ca2+ channels (LTCC), 
triggering even greater Ca2+ release from the Ca2+ stores of the cell, i.e., the sarcoplasmic 
reticulum (SR; Figure 1). This Ca2+ binds to troponin C, facilitating actin-myosin interaction 
that induces the contraction of the heart muscle. During diastole, Ca2+ diffuses away from 
troponin C, initiating relaxation. The Ca2+ that was released from the SR is taken back up by 
the SR Ca2+ ATPase (SERCA), whereas the amount of Ca2+ that entered the cell via LTCCs 
is exported by the Na+/Ca2+ exchanger (NCX).4  
 
Cardiac contractility is increased by three principle mechanisms:  
1) -Adrenergic stimulation, 
2) the Frank-Starling mechanism and 
3) the positive force-frequency relation (also known as “Bowditch-Treppe”).  
 
Noradrenaline (NA) is released from sympathetic nerve endings in the myocardium and 
stimulates 1-adrenergic receptors (1-ARs), which couple to the stimulatory G-protein (Gs) 
and activate the adenylyl cyclase (AC) to produce cAMP (Figures 1 and 2). Cyclic AMP 
activates protein kinase A (PKA) which (through phosphorylation) activates LTCCs, 
accelerates SERCA, increases SR Ca2+ release via ryanodine receptors (RyRs) and 
decreases myofilament Ca2+ affinity. Furthermore, cAMP activates the exchange protein 
directly activated by cAMP (Epac), further activating Ca2+/Calmodulin-dependent protein 
kinase II (CaMKII) which phosphorylates various Na+- and Ca2+-transporting proteins, mostly 
synergistic with PKA-mediated actions (Figure 2).21 The net result is an increase and 
acceleration of force generation and relaxation (positive inotropic and lusitropic effects), 
maintaining the refilling of the ventricles at elevated heart rates (positive chronotropic effect). 
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In the human heart, the breakdown of cAMP is governed primarily by PDE3 and to a lesser 
extent by PDE4.22 
 
Besides -AR stimulation, the “Bowditch Treppe” increases cardiac contractility at elevated 
heart rates. This is explained by slower Ca2+-efflux (via the NCX) than -influx kinetics (via 
LTCCs), which results in intracellular accumulation of Ca2+ at higher heart rates that is 
sequestered into the SR by SERCA, from where it is released in greater amounts on the 
ensuing beat. The Frank Starling mechanism is caused by a length-dependent increase of 
the Ca2+ affinity of the myofilaments, resulting in stronger contraction at unchanged cytosolic 
Ca2+ concentrations ([Ca2+]c).  
 
 
Pathophysiological changes of excitation-contraction coupling in 
heart failure 
The central deficit of EC coupling in myocytes from failing hearts is a decreased Ca2+ load of 
the SR. This is primarily the result of reduced SERCA expression and activity and a Ca2+ leak 
from the SR via RyRs, reducing systolic SR Ca2+ release and thereby the activator Ca2+ at 
the myofilaments (Figure 1).5 The reduced rate of SERCA-mediated Ca2+ re-uptake into the 
SR also slows relaxation. Furthermore, the cytosolic Na+ concentration ([Na+]i) is elevated in 
failing cardiac myocytes through changes in the “late Na+ current”, Na+/H+ exchanger (NHE) 
and Na+/K+-ATPase (NKA) activities.23 While this facilitates Ca2+-influx via the reverse-mode 
of the NCX during the action potential,5 partly compensating for decreased systolic SR Ca2+ 
release,24 relaxation is further slowed by hampering diastolic Ca2+ extrusion via the forward-
mode NCX. This is particularly problematic at higher heart rates, when diastole progressively 
shortens. Consequently, the normally positive force-frequency relationship is blunted or even 
negative in failing human hearts, mediated by a variable combination of elevated diastolic 
[Ca2+]c and tension as well as decreased SR Ca2+ load and release.25,26 This decreases left 
ventricular ejection fraction (LVEF) and cardiac output at higher heart rates in vivo.27 Finally, 
elevated diastolic [Ca2+]c and increased open probability of RyRs increases the probability of 
spontaneous SR Ca2+ release events, which (by subsequent Ca2+ extrusion via the 
electrogenic NCX) can induce delayed after-depolarizations, a well-defined trigger of 
ventricular arrhythmias.  
 
In addition to the defects in ion handling and the ensuing inversion of the force-frequency 
relationship, continuous stimulation of cardiac 1-ARs through activation of the sympathetic 
nervous system desensitizes and downregulates 1-ARs (Figure 2),7,8 blunting their 
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response to endogenous or exogenous catecholamines. Consequently, phosphorylation of 
several Ca2+ handling proteins is reduced. In failing hearts, the Ca2+ affinity of the 
myofilaments is increased as a result of decreased PKA-mediated phosphorylation of 
troponin I,28,29 although this issue is not fully settled yet.30  
 
 
Energetic aspects 
EC coupling requires high amounts of energy in the form of ATP, which is replenished by 
oxidative phosphorylation in mitochondria. During β-adrenergic stimulation, mitochondria 
take up Ca2+ to stimulate the Krebs cycle, which produces NADH as the main electron donor 
for ATP production at the respiratory chain (Figure 3).31 Mitochondrial function is impaired in 
HF, resulting in energetic deficit and oxidative stress (Figure 3).31-33 Mitochondrial 
dysfunction is linked to defects in EC coupling, since the Krebs cycle requires stimulation of 
its key enzymes by Ca2+, and decreased SR Ca2+ release hampers mitochondrial Ca2+ uptake 
via the uniporter (MCU). In addition, elevated [Na+]i accelerates mitochondrial Ca2+ efflux via 
the mitochondrial Na+/Ca2+ exchanger (NCLX; Figure 3). Impaired Krebs cycle activity limits 
NADH-dependent ATP production at the respiratory chain and provokes excess emission of 
reactive oxygen species (ROS) through depletion of the NADPH-dependent anti-oxidative 
capacity, causing oxidative stress.31 Reduced ATP production can limit the contractile reserve 
of the LV,34 and most Na+ and Ca2+ transporting mechanisms are sensitive to redox-
dependent modifications.35 Thus, the tight interplay between EC coupling and mitochondrial 
energetics (Figure 3) can set in motion a vicious cycle of deteriorated ion handling, energetic 
deficit and oxidative stress to aggravate systolic and diastolic dysfunction in HF.  
 
In patients with HF, iron deficiency (ID) predicts adverse outcome,36 while iron 
supplementation improves functional capacity and quality of life.37 In failing hearts, 
myocardial iron content is reduced and associated with reduced activity of Krebs cycle 
dehydrogenases and expression of antioxidative enzymes.38 In preclinical models, severe 
cardiac or skeletal muscle ID perturbs mitochondrial function and induces systemic metabolic 
derangements and cardiomyopathy.39,40 Accordingly, ID may further aggravate energy supply 
and demand mismatch and oxidative stress in HF. However, since plasma ID does not 
directly correlate with myocardial ID, these issues require further investigation (for more in-
depth discussion see Ref.41).  
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“Classical” inotropic agents 
 
Digitalis 
Digitalis-derived cardiotropic glycosides (CTG) are the oldest inotropic drugs and increase 
[Na+]i in cardiomyocytes by inhibiting Na+ export via the NKA (Figure 4). [Na+]i accumulation 
hampers diastolic Ca2+ extrusion via the NCX and supports Ca2+ influx via the reverse mode 
NCX during systole, thereby increasing diastolic [Ca2+], Ca2+ transient amplitudes and 
consequently, inotropy (Figure 4). On the other hand, elevated [Na+]i accelerates 
mitochondrial Ca2+ efflux via the NCLX, reducing Ca2+-activation of the Krebs cycle and its 
regeneration of NADH and NADPH. Since NADPH is required for anti-oxidative enzymes to 
detoxify ROS (Figure 3), CTG-induced NADPH oxidation increases mitochondrial ROS 
emission and thereby arrhythmias (Figure 4).42 The pro-arrhythmic actions of CTG narrow 
its therapeutic range.43  
 
In patients with HFrEF, digoxin may be considered in symptomatic patients in sinus rhythm 
despite treatment with an ACE-inhibitor (or angiotensin receptor blocker), a β-blocker and a 
mineralocorticoid antagonist to reduce the risk of hospitalizations (class IIb, B3). However, 
the Digitalis Investigation Group (DIG) Trial4 was conducted before β-blockers became a 
mainstay of HF therapy, and digoxin did not improve all-cause mortality, but reduced 
hospitalization due to HF worsening. At the lower dosages used in current practice, digitalis 
may be preferentially a modulator of autonomic tone and less inotropic stimulator.44 The 
ongoing DIGIT-HF study prospectively investigates the role of digitoxin in patients with HFrEF 
already on current guideline-adherent therapy (http://digit-hf.de). In atrial fibrillation, clinical 
evidence is limited to small and observational studies, and there is an ongoing debate on 
potentially increased mortality.45 However, prescription bias in the retrospective analyses 
likely mimics the perceived digoxin driven mortality.46 According to the current HF Guidelines, 
an intravenous bolus of digoxin should be considered in digoxin-naïve-patients in New York 
Heart Association (NYHA) class IV and rapid ventricular rate to slow heart rate (Class IIa, 
B).3 
 
 
Catecholamines 
The three endogenous catecholamines dopamine, adrenaline and noradrenaline stimulate 
1-ARs, and to variable degrees also 1- and 2-ARs and dopaminergic D1- and D2-receptors 
(Table 1).6 Thus, their hemodynamic actions are not limited to increasing cardiac contractility 
via 1-ARs (Figure 2). In fact, 1-AR-mediated vasoconstriction by adrenaline and 
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noradrenaline (Table 1) renders them useful in patients with septic shock where vasodilation 
underlies hypotension. The hemodynamic profile of dopamine, the immediate precursor to 
noradrenaline in the synthetic pathway, is dominated by vasodilation at low concentrations at 
which binding to dopaminergic D1- and D2-receptors increases blood flow to the heart, brain, 
kidney and various other organs. Its traditional use to increase renal blood flow, however, 
was discouraged after neutral effects in trials on patients with acute decompensated heart 
failure, with or without renal dysfunction.47-49 At higher doses, dopamine increases blood 
pressure by vasoconstriction via 1-ARs and positive inotropic and chronotropic effects via 
-ARs, respectively.   
 
Since in patients with cardiogenic shock, neuroendocrine activation induces vasoconstriction 
and tachycardia, the ideal drug should be positive inotropic without further increasing systemic 
vascular resistance (SVR). Dobutamine fulfils these requirements.50 It is a full agonist at 1-
ARs, inducing a positive inotropic effect with similar efficacy as isoproterenol, a synthetic 1- 
and 2-AR agonist without any -AR agonism (Table 1). The affinity of dobutamine for 2-AR 
is ~10-fold lower than for 1-ARs and in particular, its agonist efficacy at 2-ARs and 1-ARs 
much weaker than at 1-ARs.51 Through its dominating inotropic effect and mutually offsetting 
vascular effects of 1- and 2-AR agonism, the decrease of SVR at intermediate and higher 
doses is mediated by reflex withdrawal of the endogenous sympathetic tone.52 For any given 
increase in cardiac contractility, the increase of heart rate and blood pressure is lower with 
dobutamine than with dopamine or noradrenaline, further reflecting dobutamine´s selectivity 
for 1- over 2- and 1-ARs.50 However, this favorable hemodynamic profile comes at the cost 
of elevated myocardial O2 consumption50,52 and arrhythmias.  
 
Noradrenaline may be considered in patients who have cardiogenic shock despite treatment 
with another inotrope to increase blood pressure and vital organ perfusion.3 The combination 
of adrenaline with dobutamine, however, portends a particular risk for adverse outcome.53 In a 
recent meta-analysis, adrenaline was associated with a three-fold increase in mortality,54 and 
in patients with cardiogenic shock after acute myocardial infarction, refractory shock was five-
fold more frequent with adrenaline than with noradrenaline.55 For a similar effect on blood 
pressure, adrenaline (but not noradrenaline) increased heart rate (due to its strong β2-AR 
activation; Table 1) and myocardial oxygen consumption (derived from the cardiac double 
product), increasing lactate as a sign of metabolic compromise.55 These data underscore that 
adrenaline should be avoided in patients with cardiogenic shock.  
 
In patients with HF, elevated plasma noradrenaline levels predict adverse outcome.56 Chronic 
-AR stimulation desensitizes and downregulates -ARs via PKA, GRK2 (also known as -
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ARK1) and -arrestin.7,8,57 Furthermore, -arrestin activates CaMKII which sustains 
contractility despite desensitization of -ARs from PKA-mediated inotropy (Figure 2).21 
CaMKII activation, however, is a major driver of cardiac arrhythmias.58 The net functional 
consequence of all these processes is a decreased responsiveness of the human failing heart 
to -AR stimulation. Therefore, despite its favourable short-term hemodynamic profile that 
improves symptoms,9 dobutamine treatment is associated with tolerance,59 arrhythmias and 
mortality, respectively.60,61 
 
PDE Inhibitors 
To overcome desensitization and downregulation of cardiac β-ARs as well as their blockade 
through β-blockers, PDE-inhibitors were developed. In human failing myocardium, inhibition 
of PDE3, but not PDE4 potentiates β-AR mediated positive inotropic effects.62 Conversely, in 
human atrial myocardium, inhibition of PDE4 potentiates arrhythmias induced by both β1- and 
β2-AR stimulation, while PDE3 inhibition only potentiates β1-AR-induced arrhythmias.63 PDE-
inhibitors also decrease SVR through cAMP-mediated vasodilation, which is beneficial in 
patients with acute HF and high SVR, but limits its application in patients with cardiogenic 
shock due to reductions in blood pressure. In patients with HF treated with β-blockers, the 
efficacy and potency of PDE-inhibitors is maintained, while the effects of dobutamine are 
blunted.64  
 
Why have classical inotropes failed?  
Currently, dobutamine, dopamine and PDE-inhibitors are recommended in patients with 
hypotension (SBP <90 mmHg) and/or signs/symptoms of hypoperfusion despite adequate 
filling status to increase cardiac output and blood pressure and to improve peripheral 
perfusion and maintain end-organ function (IIb, C).3 However, while in analyses that 
evaluated cAMP-dependent inotropes in general, their short-term use yielded neutral effects, 
longer-term use was associated with adverse outcome in patients hospitalized for acute HF 
despite improved quality of life.60,65,66 Therefore, inotropic agents are explicitly restricted to 
patients that fulfil the above mentioned criteria and are not recommended for any other 
patients (class IIIA).3 The adverse long-term effects may be related to PKA- and CaMKII-
induced maladaptive cardiac remodeling through inducing hypertrophy, apoptosis and 
fibrosis (Figure 2).7,8 In particular, activation of 1-ARs induces apoptosis,67 which is an 
important mechanism for LV remodelling and dysfunction in HF.68,69 Furthermore, β-
adrenergic activation alters myocardial substrate utilization and thereby, may trigger 
energetic deficit and oxidative stress.61 These data indicate that despite their favourable 
acute hemodynamic profile, the use of adrenergic agonists and PDE-inhibitors leads to 
adverse outcome by triggering maladaptive cardiac remodelling and arrhythmias, while vice 
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versa, antagonizing 1-ARs can reverse remodelling, improve LV function and prolong 
survival.7 Therefore, a new generation of inotropes had to be developed to avoid activation 
of adrenergic pathways and increase contractility without raising Ca2+, which is pro-
arrhythmic and causes higher energy consumption through activation of Ca2+ transporting 
systems.   
 
 
Treatments targeting sarcomeres 
 
Ca2+ sensitizers 
Ca2+ sensitizers shift the relationship between [Ca2+]c and force development of sarcomeres 
(i.e., the pCa-force relationship) to the left, increasing force at any given [Ca2+]c. They were 
developed in the early 1980s as cardiotonic agents with a number of theoretical advantages 
over catecholamines and PDE-inhibitors:  
 
(i) Ca2+ sensitizers should neither increase trans-sarcolemmal influx of Ca2+ nor alter 
SR Ca2+ fluxes during systole or diastole. This should be less pro-arrhythmic and 
less energy consuming.  
(ii) Ca2+ sensitizers should not affect heart rate or blood pressure if a compound was 
selective for cardiac myofilaments, which may have positive effects on energetics.  
(iii) Ca2+ sensitizers should be independent of the desensitized β-AR/cAMP system in 
HF and should themselves not induce tolerance. 
 
Examples of this class of drugs are EMD-57033, CGP-48506, pimobendan and levosimendan. 
The mechanisms of Ca2+ sensitization differ between Ca2+ sensitizers. While levosimendan 
and pimobendan increase the affinity of troponin C to bind Ca2+,70-72 CGP-48506 acts 
downstream of troponin C, and EMD-57033 affects the actin-myosin interaction by direct 
binding to the myosin motor domain.73,74 Independent of the mechanism, the shift of the pCa-
force curve to the left increases systolic force generation for any given [Ca2+]c, but on the other 
hand impedes relaxation following the decrease in [Ca2+]c. The slowing of relaxation is an 
inherent property of pure Ca2+ sensitizers and may be the reason why most pharmaceutical 
companies stopped their development. In this context, mutations in sarcomeric proteins that 
cause hypertrophic cardiomyopathy (HCM) commonly increase myofilament Ca2+ sensitivity 
as a unifying disease mechanism.75,76 Moreover, both HCM mutations and drugs that increase 
Ca2+ sensitivity are arrhythmogenic, presumably by providing a sink for Ca2+ that is released 
during diastole, causing depolarisations via the electrogenic NCX.77,78  
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Levosimendan 
In contrast to CGP-48506, levosimendan does not prolong relaxation time or compromise 
diastolic relaxation. Thus, it does not have the same profile as pure Ca2+ sensitizers. The 
most likely reason is that levosimendan is not only a Ca2+ sensitizer binding to troponin C,71 
but also a potent and selective PDE3-inhibitor with an IC50 in the nanomolar range, but ~1000-
fold lower affinity for PDE4.79,80 Accordingly, levosimendan increases cAMP with similar 
potency as it increases force.81 Furthermore, its positive inotropic effect is abolished by the 
muscarinic receptor agonist carbachol, which acts through inhibiting cAMP generation. Also 
in human myocardium, the inotropic effects of levosimendan require β-adrenergic pre-
stimulation and/or elevations of [Ca2+]c and can be prevented by PDE3-, but not PDE4-
inihibition.82-84  
 
Levosimendan´s clinical activity during long-term treatment is mainly governed by its active 
metabolite OR-1896, which has a much longer half-life (81 vs. 1 h85). OR-1896 stimulated 
contractile force with a roughly similar potency as levosimendan, had a 4.5-fold lower potency 
as a Ca2+ sensitizer and a 38-fold lower potency as a PDE3 inhibitor.80 Yet, even the inotropic 
effect of OR-1896 is sensitive to carbachol and therefore likely mediated by PDE3 inhibition.86 
Therefore, also for OR-1896, a combination of PDE3-inhibition with Ca2+ sensitization is the 
mechanism that is responsible for positive inotropy.  
 
A common alternative explanation why levosimendan does not prolong relaxation (other than 
through PDE3-inhibition) is that levosimendan´s binding to troponin C is Ca2+-dependent. 
However, it is currently unclear – if not rather unlikely – whether levosimendan can bind and 
unbind troponin C on a beat-to-beat basis in a millisecond and micromolar range, as would 
be required to explain the lack of relaxation prolongation by this mechanism (see the Online 
Supplement for a detailed discussion of this issue). Besides its effects on EC coupling, 
levosimendan also activates glibenclamide-sensitive sarcolemmal ATP-dependent K+-
currents (IKATP), which may add to its vasodilating activity and potentially provide 
cardioprotective effects through activation of mitochondrial IKATP (see Online Supplement for 
a more detailed discussion).    
 
These data indicate that for levosimendan, PDE3 inhibition synergizes with Ca2+ sensitization 
for its inotropic action (Figure 5), which may be particularly relevant to human failing 
myocardium in which PDE3 plays the dominant role for controlling intracellular cAMP.62 From 
this it can be predicted that the more β-ARs are pre-activated by endogenous or exogenous 
catecholamines, the more pronounced is the inotropic effect of levosimendan, and the more 
this effect is mediated by PDE3-inibition rather than Ca2+ sensitization. Conversely, at low β-
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AR pre-activation (such as during pharmacological β-blockade), the Ca2+ sensitization effect 
of levosimendan may become more important for inotropy. In this context, it is interesting to 
observe that in the SURVIVE trial, patients with (but not without) β-blocker pre-treatment had 
improved short-term survival with levosimendan compared to dobutamine.87,88 Conversely, in 
patients with septic shock who were all co-treated with catecholamines, levosimendan was 
associated with higher rates of supraventricular tachycardia and a numerical, but non-
significant increase in mortality (hazard ratio 1.24, p=0.17).89 Therefore, although the clinical 
evidence for these considerations is limited, levosimendan´s PDE3-inhibitory effect may be 
potentiated through pre-activation of β-ARs by endogenous or exogenous catecholamines 
also under in vivo conditions, and such potentiated adrenergic signaling may potentially 
contribute to arrhythmias and adverse consequences for cardiomyocyte biology (Figure 2).    
 
Clinical trials 
Several clinical trials tested the effects of levosimendan in patients with HF, comparing it to 
either placebo or dobutamine. In the LIDO trial, levosimendan improved hemodynamics more 
effectively than dobutamine and was associated with lower mortality than dobutamine after 
180 days.90 In the SURVIVE trial, however, mortality after 180 days (the primary endpoint) 
was not different between dobutamine and levosimendan despite a more favourable 
hemodynamic profile (BNP reduction) in the first 5 days after randomization.12 As mentioned 
above, pre-treatment with a β-blocker was associated with improved short-term outcome at 
day 5 in a posthoc analysis.87 
  
In the REVIVE trial,13 levosimendan (compared to placebo) was associated with more 
frequent hypotension and cardiac arrhythmias during the infusion period, and a numerical 
(but insignificant) risk of death despite improved symptoms and reduced plasma BNP levels. 
In a meta-analysis on 5,480 patients in 45 randomized clinical trials, however, levosimendan 
was associated with a 20% relative risk reduction of mortality, and this reduction was 
confirmed in studies with placebo (-18%; p<0.05) or dobutamine as comparator (-32%; 
p<0.005).10 These trends were confirmed by another meta-analysis.11 However, in these 
meta-analyses, trials on patients with acute cardiac events were combined with trials on 
patients undergoing elective cardiac surgery. Furthermore, in the recent CHEETAH14 and 
LEVO-CTS15 trials, levosimendan did not improve outcome of patients with systolic HF 
undergoing cardiac surgery, although the use of inotropes 24 hours after surgery was 
reduced with levosimendan in LEVO-CTS.15 
 
Several smaller trials evaluated the usefulness of repeated doses of levosimendan for 
patients with advanced HF in outpatient settings. Posthoc- and meta-analyses of these 
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mostly underpowered trials suggest that levosimendan may have favourable effects on 
hemodynamics, symptoms, rehospitalisation and biomarkers.91 In the recent LION-HEART 
study on 69 patients with advanced HF, biweekly infusions of levosimendan for 12 weeks 
reduced NT-proBNP, improved quality of life and reduced hospitalization without adverse 
effects.92 Therefore, the initiation of a larger trial to test this treatment strategy for advanced 
HF patients is warranted.  
 
Taken together, the principle of Ca2+ sensitization alone was no breakthrough in the treatment 
of the common forms of HF, because it is associated with worsening of diastolic relaxation, 
which is already compromised in HF in the first place. The ancillary PDE-inhibitory effect of 
levosimendan improves its hemodynamic profile compared to other, more pure Ca2+ 
sensitizers, although this may come at the cost of cAMP-related side effects (e.g., 
arrhythmias). So far, there is no clear evidence that levosimendan improves survival 
compared to placebo or a comparator drug.  
 
Based on its clinical profile, the current HF Guidelines make the following recommendations 
for the use of levosimendan:  
• Short-term intravenous infusion of levosimendan may be considered in patients with 
hypotension (SBP <90 mmHg) and/or signs/symptoms of hypoperfusion despite 
adequate filling status to increase cardiac output and improve peripheral perfusion 
and maintain end-organ function (similar to dobutamine, dopamine and PDE-
inhibtors; IIb, C).3 
• When mean arterial pressure needs pharmacological support, a vasopressor 
(preferably noradrenaline) may be used in combination with levosimendan.3  
• An intravenous infusion of levosimendan (or a PDE inhibitor) may be considered to 
reverse the effect of β-blockade if β-blockade is thought to be contributing to 
hypotension with subsequent hypoperfusion (IIb, C).3 
• Levosimendan is not recommended unless the patient is symptomatically 
hypotensive or hypoperfused because of safety concerns (IIIA).3  
 
 
Omecamtiv mecarbil 
Omecamtiv mecarbil (OM) is a small-molecule, selective cardiac myosin activator whose 
therapeutic rationale and discovery were described elsewhere.93,94 OM binds to the catalytic 
domain of cardiac myosin, stabilizing the pre-powerstroke state,95 thus increasing the 
transition rate of myosin into the strongly actin-bound force-generating state (Figure 6A)96 
and thus increasing cardiac contractility. The pharmacodynamic signature of OM is an 
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increase in the systolic ejection time (SET). This is a consequence of the increase in the 
number of myosin heads interacting with actin filaments, facilitating a longer duration of 
systole, even as [Ca2+]c already decays. OM prolongs the time and increases the amplitude, 
but not the rate of cell shortening, and does not interfere with [Ca2+]c transients (Figure 6B).96  
 
A number of dose-finding studies with an intravenous formulation of OM were performed in 
a dog model of HF,97 healthy men17 and patients with acute19 and chronic HF,16 respectively. 
In the dog HF model, OM prolonged SET and increased stroke volume (SV; Table 2).96, 97 
Consequently, cardiac output increased, thereby decreasing SVR and heart rate, presumably 
through reducing endogenous sympathetic activation.96,97 Although OM might increase ATP 
turnover at the level of the sarcomere,96 this increase appears to be counterbalanced by the 
reduction in heart rate, SVR (reducing cardiac afterload) and end diastolic volume (reducing 
myocardial wall stress), resulting in no significant change of cardiac O2 consumption despite 
the increase of cardiac output.96,97 Consequently, cardiac efficiency should improve.  
 
In healthy men and patients with stable HF, at comparable increases in SET, however, the 
net increases in SV, cardiac output and the ensuing decreases in heart rate were overall 
smaller than in the preclinical studies, perhaps reflecting the broader range of baseline 
conditions found in human studies (Table 2). In these early studies, OM was studied over a 
broad range of plasma concentrations, in some cases exceeding 1200 ng/ml. Increases in 
SET are noted at plasma concentrations as low as 100-200 ng/ml, while the effect on SV 
appeared to plateau at 400-500 ng/ml. In some individuals, myocardial ischemia developed 
with chest pain, ECG changes and/or troponin rises at plasma concentrations beyond 1200 
ng/ml.16,17 This may be explained by an excessive increase in SET, prolonging cardiac 
contraction, and progressively shortening diastole (during which coronary perfusion takes 
place).16,17 In a trial of patients with ischemic cardiomyopathy and angina in daily life, 
however, OM at target plasma concentrations of 295 ng/ml and 550 ng/ml, respectively, did 
not affect symptom-limited exercise capacity in treadmill tests or plasma troponin I levels.18 
Subsequent trials focused on dose regimens that constrain exposure to less than 1000 ng/ml. 
 
In the ATOMIC-AHF study on patients with AHF and an LVEF ≤40%, the primary endpoint of 
dyspnea relief was not reached by 3 ascending doses of intravenous infusion of OM versus 
placebo.19 However, in the highest dose group (n=202), more patients responded with 
dyspnea relief to OM (51%) than to placebo (37%; p=0.034). In an echocardiographic 
substudy, OM prolonged SET and decreased LV end-systolic dimension, although LV stroke 
volume was not increased.19 Additionally, slight decreases in heart rate (-2 bpm) and 
increases in systolic blood pressure were noted (Table 2).  
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In the COSMIC-HF trial, oral OM at either a fixed dose (25 mg twice daily) or dosing based 
on a pharmacokinetic titration protocol was tested against placebo in patients with stable (not 
acute) systolic HF receiving standard of care therapy.20 After 20 weeks, moderate increases 
in SET and SV and a slight reduction in heart rate were noted in the pharmacokinetic titration 
group (Table 2). The latter effect may reflect slightly reduced endogenous sympathetic 
activity.98 Furthermore, the LV end-diastolic volume decreased by 11 ml and NT-proBNP 
levels dropped by 970 pg/ml compared to placebo, respectively. As in ATOMIC-AHF,19 there 
was a small increase in cardiac troponin I that did not correlate with OM plasma 
concentrations.16,17 The frequency of deaths, arrhythmias, hospital admissions or adverse 
events was not different between groups, suggesting safety.  
 
Overall, the hemodynamic profile of OM appears promising within its therapeutic range. The 
increase in cardiac contractility and subsequent prolongation of SET increases LV stroke 
volume in patients with chronic HF and consequently, blood pressure should rise initially 
which then may reduce endogenous sympathetic activation. This is indicated by the slight, 
though consistent lowering of heart rate in human and animal studies. As a result, cardiac 
output in humans appears largely unchanged despite the modest decrease in heart rate, 
suggesting improved cardiac efficiency. Furthermore, the decrease in LV filling pressures, as 
indicated by the decrease in NT-proBNP in COSMIC-HF or the decrease of LV end-diastolic 
pressures in acute studies in the dog indicate LV unloading that may facilitate reverse 
remodeling of the LV. The now initiated GALACTIC-HF trial (NCT02929329), which aims to 
include 8000 patients with chronic HF will eventually clarify the long-term outcome by OM. 
Meanwhile, some uncertainties remain regarding the mechanisms of action of OM and their 
implications for cardiac function and long-term outcome.  
 
Diastolic dysfunction  
In cardiac myocytes, the increase in systolic function by OM comes at the cost of increased 
diastolic tension (Figure 6C), indicated by shortening of diastolic cell length. At low [OM] of 
200-400 nM, systolic improvement outweighs the diastolic deficit in rat cardiac myocytes, 
while at 800 nM, this relation reverses. In an in vivo pig model of myocardial stunning after 
ischemia/reperfusion, OM reduced both end-diastolic and end-systolic volumes to similar 
extents (Figure 6E) at concentrations that prolonged SET by 20% (table 2). Thereby LVEF 
pseudo-increased, while SV did not.99 Furthermore, the OM-induced increase in cardiac 
output was smaller in humans with or without HF compared to the dogs with HF (table 2). In 
light of the results on post-ischemic pigs,99 it needs to be considered whether an improvement 
of SET (and therefore, SV) by OM may have been (partly) offset by decreases in end-diastolic 
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volume or filling. The improvement of NT-proBNP by long-term OM in COSMIC-HF,20 
however, rather argues against a meaningful deterioration of diastolic function by these doses 
of OM.  
 
Bioenergetic aspects 
In dogs with HF, OM did not increase O2 consumption97 although in the post-ischemic pig 
model, O2 consumption tended to increase.99 In isolated mouse hearts, OM impaired 
myocardial efficacy by increasing O2 consumption in working hearts and during basal (resting) 
metabolism, which was abolished by a myosin-ATPase inhibitor.99 These data suggest that 
OM increases (tonic) myosin ATPase activity100 and thereby O2 consumption, which however 
contrasts with the effect of OM to inhibit the basal ATPase of myosin in vitro.101 In skinned rat 
cardiac myocytes, OM shifted the pCa/force relationship to the left, indicative of sensitizing 
myofilaments to Ca2+ (Figure 6F).102 In human myocardium, OM increased the myosin duty 
ratio which resulted in enhanced Ca2+ sensitivity, but slower force development.103 In a mouse 
model of dilated cardiomyopathy with decreased myofilament Ca2+ sensitivity, OM resensitized 
myofilaments towards control levels.104 However, in the majority of patients with HF, the Ca2+ 
affinity of the myofilaments is increased rather than decreased,28-30,105,106 and in LV 
myocardium of patients with terminal HF, increased diastolic tension consumes as much ATP 
and O2 as systolic tension, and elevated diastolic tension is a substantial energetic burden in 
failing hearts especially at higher heart rates.107 
 
In conclusion, whether OM has a neutral or even net energy-sparing effect on myocardial 
bioenergetics, or whether the drug´s net effect on myosin could increase O2-consumption is 
a question future research should continue to address. Furthermore, the development of 
small molecules targeting sarcomeric motor proteins is an emerging field that is discussed in 
more detail in the Online Supplement.  
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Alternative treatments targeting EC coupling  
 
Nitroxyl 
Nitroxyl (HNO) is produced by NO synthase under conditions of oxidative or nitrosative stress. 
HNO donated by Angeli’s salt (AS) improves cardiac function in normal and failing dogs, 
independently of β-AR signaling, with no change in cGMP levels.108,109 In cardiac myocytes, 
HNO increases fractional shortening (FS) and Ca2+ transients with no involvement of 
cAMP/PKA or cGMP/protein kinase G signaling.110 Instead, HNO modifies cysteine residues 
to enhance Ca2+ handling and increase myofilament Ca2+ sensitivity. In particular, HNO alters 
the inhibitory interaction between phospholamban and SERCA2a in a redox-dependent 
manner, improving SR Ca2+ uptake and release in isolated myocytes/hearts (Figure 7).111,112 
In addition, HNO modifies the actin-tropomyosin and myosin heavy chain-myosin light chain 1 
interactions, increasing Ca2+ sensitivity and force generation in intact and skinned muscles 
(Figure 7).113 
 
Whereas beneficial effects of NO signaling to cGMP may be lost in conditions of cardiac 
oxidative stress (by the high reactivity of NO with ROS), this does not occur with HNO, whose 
efficacy is preserved in conditions with altered redox balance.114,115 Novel HNO donors (e.g. 
CXL-1020) are long-lasting and more specific. CXL-1020 has HNO-dependent positive 
inotropic and lusitropic effects in isolated cardiac myocytes in vitro and in whole animal studies 
in vivo, in both normal and failing conditions. Human phase I-IIa clinical trials were recently 
completed (NCT01092325, NCT01096043). In patients with systolic HF, CXL-1020 reduced 
both left and right heart filling pressures and SVR, while increasing SV. Heart rate was 
unchanged, and arterial pressure declined modestly.116 Currently, an improved second-
generation HNO donor, CXL-1427, is tested in Phase I and II trials on healthy volunteers and 
patients with HF (NCT02157506, NCT02819271).   
 
Other compounds and interventions 
The mechanisms and, where appropriate, clinical results of Istaroxime, SERCA2a gene 
therapy and EF hand proteins are discussed in the Online Supplement.   
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Energetic considerations 
Taken together, inotropic agents have three principal modes of action:  
 
1) Activation of the adrenergic system,  
2) sensitization of myofilaments to Ca2+ and  
3) reconstitution of cytosolic Ca2+ handling independent of adrenergic activation.  
 
The modes of action of inotropic drugs have important energetic consequences. Most cellular 
ATP is consumed by SERCA, NKA and myosin ATPase.117 A central mechanism to match 
ATP supply to demand is “parallel activation” by Ca2+,31 where Ca2+ activates both ATP 
consumption and -regeneration (Figures 3 and 8): Increases in [Ca2+]c accelerate ATP 
consumption by EC coupling, hastening respiration via ADP which oxidizes NADH and 
FADH2 at the respiratory chain. On the other hand, Ca2+ enters mitochondria to activate Krebs 
cycle dehydrogenases, accelerating NADH and FADH2 regeneration (Figure 8).31 
Consequently, hormones or drugs that increase Ca2+ handling (e.g., catecholamines) in the 
short term induce this “parallel activation” of respiration, maintaining the redox state of NADH 
and FADH2 in normal hearts (Figure 8).31 In the failing heart, however, mitochondrial Ca2+ 
uptake is impaired, resulting in NADH oxidation during β-adrenergic stimulation.31,33 Since 
NADH is coupled to the NADPH pool, and NADPH required for ROS detoxification (Figures 
3 and 8), a mismatch between cardiac work and mitochondrial Ca2+ uptake induces oxidative 
stress.31,33 This may contribute to arrhythmias, systolic dysfunction and maladaptive 
remodeling through necrosis and other redox-sensitive signaling pathways.33 Therefore, 
improving SR Ca2+ content and release, as has been observed with AAV1/SERCA2a118 or 
HNO110 in animal models of HF, may improve the efficiency of mitochondrial Ca2+ uptake and 
make the failing heart less sensitive towards β-AR-mediated oxidative stress and damage. 
In patients with improved LVEF in response to β-blockers, SERCA gene expression was 
strongly upregulated,119 suggesting that also β-blockers may improve mitochondrial redox 
regulation through restoring defective EC coupling in the long term.  
 
Conversely, when sensitizing myofilaments to Ca2+, the increase in ATP consumption at the 
myofilaments may not be adequately matched by Ca2+-induced Krebs cycle activation in 
mitochondria (Figure 8). In fact, pre-stretching cardiac trabeculae increases force production 
independent of an increase in Ca2+ via the Frank Starling mechanism, which is related to 
myofilament Ca2+ sensitization, and this oxidizes NADH.120 Whether such energetic mismatch 
and possibly further downstream consequences such as energetic deficit and oxidative stress 
are also the result of Ca2+ sensitization through inotropic drugs (i.e., EMD-57033, 
levosimendan, OM, nitroxyl etc.), mutations occurring in patients with HCM75,76 and/or post-
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translational modifications occurring in patients with systolic HF106 needs to be clarified by 
future research. In the context of inotropic drugs, however, a profile where Ca2+ sensitization 
is coupled to restoration of Ca2+ handling (i.e. nitroxyl) or increases of Ca2+ (i.e., 
levosimendan; table 3) may ameliorate energetic/redox mismatch occurring through Ca2+ 
sensitization per se.  
 
Finally, it should be considered whether targeting mitochondria may be an alternative indirect 
inotropic intervention, since in dogs with HF, elamipretide – which accumulates in 
mitochondria and improves mitochondrial function – acutely increased cardiac output by a 
similar extent (+25%)121 as OM (+22 and +29%, respectively; Table 2).96, 97 Furthermore, 
trimetazidine and perhexilline target substrate metabolism of mitochondria and improve 
LVEF, hemodynamics, cardiac energetics and symptoms in patients with HF (for more details 
on these compounds see Online Supplement).122-126 Finally, cardiac myocyte-specific iron 
deficiency impaired the response to dobutamine in preclinical models of HF which could be 
restored by iron supplementation,127 suggesting that pharmacological restoration of 
mitochondrial function may also regenerate the heart´s response to inotropic stimulation.  
 
 
Summary 
Catecholamines and PDE-inhibitors are associated with excess mortality presumably related 
to the induction of arrhythmias in the short term and the activation of signaling pathways that 
aggravate maladaptive remodelling of the failing heart in the long term. Although 
levosimendan has so far been viewed as a Ca2+ sensitizer, its inotropic effect relies on PDE3-
inhibition as well. As a myosin activator, OM improves systolic function without activating 
adrenergic signaling or increasing cytosolic Ca2+, but its therapeutic range is limited by 
diastolic dysfunction at higher doses. Nitroxyl restores cytosolic Ca2+ handling in failing hearts 
without activating cAMP-dependent signaling pathways and shows a promising 
hemodynamic profile, but its clinical usefulness awaits further clinical testing. Besides the 
impact of adrenergic signaling, bioenergetic aspects need to be considered to estimate the 
comprehensive profile and long-term consequences of any agent that affects inotropy.  
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Statements and recommendations 
Based on these preclinical and clinical data as well as the bioenergetic considerations, the 
Committees on Translational Research and on Acute Heart Failure of the HFA of the ESC 
make the following statements and recommendations:  
• Currently available drugs primarily targeting inotropy are cardiotropic glycosides, 
catecholamines (in particular, dobutamine), PDE-inhibitors and levosimendan.  
• According to the current HF Guidelines,3 the use of catecholamines, PDE-inhibitors 
and levosimendan should be limited to patients with hypotension (SBP <90 
mmHg) and/or signs/symptoms of hypoperfusion despite adequate filling status to 
increase cardiac output and improve peripheral perfusion to maintain end-organ 
function (IIb, C).  
• PDE-inhibitors and levosimendan can cause hypotension due to vasodilatory 
actions.   
• Vasopressors (preferably norepinephrine) may be considered to increase blood 
pressure and vital organ perfusion in patients with cardiogenic shock despite the use 
of inotropes (IIb, B).3  
• So far, all inotropic drugs recommended for the use in patients with acute HF 
(including levosimendan) activate adrenergic signaling at least to some extent.  
• Longer-term use of drugs that exclusively target adrenergic signaling 
(catecholamines, PDE-inhibitors) are associated with adverse outcome.   
• Levosimendan, with its hybrid Ca2+ sensitization and adrenergic action (PDE3 
inhibition), could be useful in selected patient populations, which may include 
patients treated with β-blockers and patients with advanced HF in an outpatient 
setting (repeated dosing) to reduce hospitalization and improve quality of life, 
although this requires additional proof from larger trials.     
• Since mitochondrial function is intimately linked to cellular Ca2+ handling,31 the 
bioenergetic consequences of treatments targeting inotropy need to be considered to 
understand their short- and long-term consequences.  
• On theoretical grounds, treatments that restore the defects of cytosolic Ca2+ 
handling in the failing heart without activating adrenergic signaling may be a 
promising avenue since they avoid diastolic dysfunction and potentially bioenergetic 
mismatch of pure Ca2+ sensitization, but also adverse long-term consequences of 
adrenergic activation.  
• Future research should be directed towards deepening our understanding of the 
close interplay between EC coupling and mitochondrial energetics, since only 
the integration of these aspects will resolve the net biological effects of drugs targeting 
inotropy in the short- and long-term.  
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Figure legends 
 
 
Figure 1: The physiology of excitation-contraction coupling and how this is altered in 
systolic heart failure.   
AR, adrenergic receptor; PDE, phosphodiesterase; cAMP, cyclic adenosine monophosphate; 
PKA, protein kinase A; SR, sarcoplasmic reticulum; SERCA, SR Ca2+ ATPase; RyR, 
ryanodine receptor; ICa and INa, Ca2+ and Na+ currents; NCX; Na+/Ca2+-exchanger; NKA, 
Na+/K+-ATPase; ETC, electron transport chain; T-tubule, transversal tubule. Red arrows () 
indicate the direction of change in heart failure.  
 
 
Figure 2: Signal transduction of β1-adrenergic stimulation in cardiac myocytes and its 
impact on inotropy, but also arrhythmias, hypertrophy and apoptosis.  
ADR, adrenaline; NA, noradrenaline; AR, adrenergic receptor; AC, adenylyl cyclase; cAMP, 
cyclic adenosine monophosphate; PDE, phosphodiesterase; PKA, protein kinase A; EPAC, 
exchange protein directly activated by cAMP; 5’-AMP, 5’ adenosine monophosphate; 
CaMKII, Ca2+/calmodulin-dependent protein kinase II; GRK2, G-protein coupled receptor 
kinase 2; α, β, γ,  α-, β- and γ-subunits of the stimulatory G-protein.    
 
 
Figure 3: Interplay between EC coupling and mitochondrial energetics.  
Krebs cycle activity is controlled by Ca2+, and mitochondrial Ca2+ uptake is diminished in heart 
failure by changes in cytosolic Ca2+ and Na+ handling. This provokes an energetic deficit and 
oxidative stress, which further impairs EC coupling and aggravates systolic and diastolic 
function.  
Nnt, nicotinamide nucleotide transhydrogenase; ETC, electron transport chain; ATPase, 
F1Fo-ATP synthase; IDPm, isocitrate dehydrogenase; Mn-SOD, mitochondrial superoxide 
dismutase; CK, creatine kinase; Cr, creatine; PCr, phosphocreatine; SERCA, SR Ca2+ 
ATPase; RyR, ryanodine receptor; late INa, late Na+ current; NCLX, mitochondrial Na+/Ca2+-
exchanger; MCU, mitochondrial Ca2+ uniporter; CaMKII, Ca2+/calmodulin-dependent protein 
kinase II; AR, adrenergic receptor. Red arrows () indicate the direction of change in heart 
failure. 
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Figure 4: Mechanisms of action of cardiotonic glycosides (CTG) and istaroxime (ISTA).  
ROS, reactive oxygen species; SR, sarcoplasmic reticulum; SERCA, SR Ca2+ ATPase; RyR, 
ryanodine receptor; ICa and INa, Ca2+ and Na+ currents; NCX; Na+/Ca2+-exchanger; NKA, 
Na+/K+-ATPase; NCLX, mitochondrial Na+/Ca2+-exchanger; TCA, tricarboxylic acid (Krebs) 
cycle. Red arrows () indicate the direction of change in response to CTG.   
 
 
Figure 5: Mode of action of levosimendan and its active metabolite OR-1896.  
Both Ca2+-sensitization and PDE3-inhibition at nanomolar concentrations ([nM]) contribute to 
their inotropic and lusitropic effects. Activation of mitochondrial KATP (mitoKATP) channels at 
micromolar concentrations ([µM]) may provide protection against ischemia/reperfusion.     
AR, adrenergic receptor; PDE, phosphodiesterase; cAMP, cyclic adenosine monophosphate; 
PKA, protein kinase A; SR, sarcomplasmic reticulum; SERCA, SR Ca2+ ATPase; RyR, 
ryanodine receptor; ICa and INa, Ca2+ and Na+ currents; NCX; Na+/Ca2+-exchanger; NKA, 
Na+/K+-ATPase; ETC, electron transport chain; T-tubule, transversal tubule. Red arrows () 
indicate the direction of change in heart failure, while green arrows () indicate the direction 
induced by levosimendan.  
 
 
Figure 6: Mechanism of action and effects of omecamtiv mecarbil.  
A, The mechanochemical cycle of myosin. Yellow indicates myosin weakly bound to actin, 
while red indicates the myosin strongly bound to actin. Omecamtiv mecarbil (OM) accelerates 
the transition rate of myosin into the strongly actin-bound force-generating state. B, 
Representative tracings showing that OM (200 nM) increases the time and amplitude of 
myocyte shortening without any effect on the cytosolic Ca2+ transient. In contrast, the β-AR 
agonist isoproterenol increases myocyte shortening through increasing cytosolic Ca2+ 
transients. Fractional systolic sarcomere shortening and diastolic cell length (C) as well as 
time to peak and maximal relaxation velocity (D) in isolated rat cardiac myocytes in response 
to escalating concentrations of OM. A-D are from Malik et al. 96 with permission. E, Impact of 
OM (20 min infusion at a dose that prolonged SET by 20%) on LV pressure-volume loops in 
a pig model of myocardial stunning (termed “post-ischemic” heart). The volumes indicate LV 
stroke volume and end-diastolic volume, of which EF is calculated. Taken from Bakkehaug 
et al. 99 with permission. F, The impact of OM at 0.1 or 1 µM on normalized isometric force in 
response to increasing Ca2+ concentrations (decreasing pCa) in skinned rat cardiac 
myocytes. Taken from Nagy et al. 102 with permission. 
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Figure 7: Mechanisms of action of nitroxyl (HNO) in HF. HNO affects redox-
sensitive residues of various proteins involved in myocyte Ca2+ handling. In particular, 
HNO increases SERCA activity and sensitizes myofilaments to Ca2+. In concert, 
these properties increase SR Ca2+ load, systolic Ca2+ transients and contraction. Red 
arrows () indicate the direction of change in heart failure, while green arrows () 
indicate the direction induced by HNO.  
 
Figure 8: Known and hypothesized bioenergetic consequences of inotropic 
interventions that either increase cytosolic Ca2+ or myofilament Ca2+ sensitivity. ECC, 
excitation-contraction coupling; ETC, electron transport chain; MCU, mitochondrial Ca2+ 
uptake.  
 
Summarizing Illustration:  
In systolic HF, contractile dysfunction is primarily related to attenuated increases in cytosolic Ca2+ during 
systole. This is the result of decreased activity of the sarcoplasmic reticulum (SR) Ca2+ ATPase 
(SERCA) and leaky ryanodine receptors (RyR). Maximal contractility is further limited by decreased 
adenosine triphosphate (ATP) production in mitochondria. Dobutamine and norepinephrine activate 
β1-adrenergic receptors (β1-AR), increasing cAMP which phosphorylates protein kinase A (PKA). PKA 
in turn phosphorylates proteins involved in EC coupling and thereby accelerates the kinetics and 
amounts of cytosolic Ca2+ during systole. The phosphodiesterase 3 (PDE3) inhibitors enoximone and 
milrinone potentiate β-AR-induced cAMP elevations and therefore, have similar effects on inotropy as 
dobutamine, increasing Ca2+ fluxes. Digitalis inhibits the Na+/K+-ATPase (NKA) and thereby elevates 
intracellular Na+, which in turn elevates Ca2+ by hampering cytosolic Ca2+ export via the forward mode 
Na+/Ca2+ exchanger (NCX) and may increase reverse mode NCX-mediated Ca2+ influx during the early 
phase of the action potential. Istaroxime has similar effects as digitalis but also activates SERCA to 
accelerate diastolic Ca2+ uptake into the SR. SERCA2a gene therapy increases the mRNA and protein 
levels of SERCA and thereby, potentiates SR Ca2+ uptake and release. Nitroxyl (HNO) activates 
SERCA activity and increases myofilament Ca2+ sensitivity. Levosimendan increases the affinity of 
troponin C to Ca2+ and thereby, increases force generation for any given cytosolic Ca2+ concentration. 
In addition, levosimendan inhibits PDE3, which elevates cAMP and PKA activity with subsequent effects 
on Ca2+ handling as described above for catecholamines and PDE-inhibitors. Omecamtiv mecarbil is 
a myosin activator that prolongs actin-myosin interaction and thereby, results in a prolongation (but not 
acceleration) of contraction. Elamipretide (also known as Bendavia or MTP-131) binds to cardiolipin 
in the inner mitochondrial membrane, increasing ATP production and reducing the generation of reactive 
oxygen species (ROS). Trimetazidine and perhexilline optimize substrate utilization and thereby, 
improve cardiac energetics. Iron restores iron deficiency and thereby, may improve function of Krebs 
cycle enzymes and possibly, the electron transport chain (ETC).  
